{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-141085","form_type":"8-K","ticker":"ELVN","cik":"0001672619","company_name":"Enliven Therapeutics, Inc.","filed_at":"2025-06-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.287679+00:00","generated_at":"2026-05-19T06:35:09.485663+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Enliven Therapeutics prices $200M public offering of common stock and pre-funded warrants","bullets":["Offering of 8.39M shares at $19.66/share and 1.78M pre-funded warrants at $19.659/warrant; gross proceeds ~$200M.","Underwriters granted 30-day option to purchase additional 1.53M shares; expected close June 16, 2025.","Net proceeds including option exercise expected ~$216.1M, for working capital and general corporate purposes.","Joint book-runners: Jefferies, Goldman Sachs, TD Cowen, Mizuho; LifeSci Capital as lead manager."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-141085","json":"https://secwatch.observer/filing/0001193125-25-141085.json","markdown":"https://secwatch.observer/filing/0001193125-25-141085.md","text":"https://secwatch.observer/filing/0001193125-25-141085.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1672619/000119312525141085/0001193125-25-141085-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1672619/000119312525141085/d150245d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T06:35:09.485663+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}